Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Primary Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT04692831
What this trial is testing

Testing a New Imaging Agent to Identify Cancer

Who this might be right for
HER-2 Positive Malignant Carcinoma of BreastHER-2 Protein OverexpressionHER2-positive Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 60
Large-scale testing (Phase 3)Study completedNCT00288002
What this trial is testing

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Who this might be right for
Breast Cancer
GBG Forschungs GmbH 1,500
Large-scale testing (Phase 3)Looking for participantsNCT05063136
What this trial is testing

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

Who this might be right for
Breast Cancer
Henan Cancer Hospital 1,979
Not applicableApproved For MarketingNCT04100694
What this trial is testing

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Who this might be right for
NRG1 FusionPancreatic CancerNon Small Cell Lung Cancer+8 more
Merus B.V.
Testing effectiveness (Phase 2)WithdrawnNCT00434031
What this trial is testing

CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Institute, Naples
Testing effectiveness (Phase 2)Looking for participantsNCT05985655
What this trial is testing

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)+3 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. 230
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Testing effectiveness (Phase 2)Ended earlyNCT04191382
What this trial is testing

Phase 2 Window Study of SAR439859 (Amcenestrant) Versus Letrozole in Post-menopausal Patients With ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer

Who this might be right for
Breast Cancer
Sanofi 105
Large-scale testing (Phase 3)Study completedNCT00553358
What this trial is testing

Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 455
Large-scale testing (Phase 3)Study completedNCT01772472
What this trial is testing

Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,486
Large-scale testing (Phase 3)Study completedNCT00490139
What this trial is testing

ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D

Who this might be right for
Neoplasms, Breast
Novartis Pharmaceuticals 8,381
Testing effectiveness (Phase 2)Study completedNCT03395899
What this trial is testing

Pre-operative Immunotherapy Combination Strategies in Breast Cancer

Who this might be right for
Breast CancerEstrogen Receptor-positive Breast Cancer
Queen Mary University of London 71
Post-approval studies (Phase 4)Study completedNCT05631795
What this trial is testing

Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 40
Testing effectiveness (Phase 2)UnknownNCT00931450
What this trial is testing

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Who this might be right for
Breast Cancer
Institut Català d'Oncologia 70
Testing effectiveness (Phase 2)Study completedNCT01548677
What this trial is testing

Efficacy Study of Herceptin to Treat HER2-negative CTC Breast Cancer

Who this might be right for
Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastCirculating Tumor Cells
European Organisation for Research and Treatment of Cancer - EORTC 1,317
Large-scale testing (Phase 3)Study completedNCT00770809
What this trial is testing

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Male Breast CarcinomaStage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7+3 more
National Cancer Institute (NCI) 305
Testing effectiveness (Phase 2)Ended earlyNCT01919229
What this trial is testing

A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)

Who this might be right for
Early Breast Cancer
Novartis Pharmaceuticals 14
Testing effectiveness (Phase 2)Ended earlyNCT03519178
What this trial is testing

PF-06873600 in People With Cancer

Who this might be right for
HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Pfizer 155
Large-scale testing (Phase 3)Study completedNCT01966471
What this trial is testing

Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 1,846
Next Page